Report: The influence of Refnot on angiogenesis
Comparative randomized study of REFNOT combined with chemotherapy in the FEC regime, REFNOT combined with INGARON and chemotherapy, and only FEC chemotherapy for treating regional and metastatic breast cancer (Phase II/III)
The study of REFNOT product safety, tolerability and efficiency for the patients with dermoid head and neck cancer. (I phase)
The influence of REFNOT on the immunoprotection of oncologic patients
